BACKGROUND & AIMS: Hepatorenal syndrome (HRS) type 1 is a progressive functional renal failure in subjects with advanced liver disease. The aim of this study was to evaluate the efficacy and safety of terlipressin, a systemic arterial vasoconstrictor, for cirrhosis type 1 HRS. METHODS: A prospective, randomized, double-blind, placebo-controlled clinical trial of terlipressin was performed. Subjects with type 1 HRS were randomized to terlipressin (1 mg intravenously every 6 hours) or placebo plus albumin in both groups. The dose was doubled on day 4 if the serum creatinine (SCr) level did not decrease by 30% of baseline. Treatment was continued to day 14 unless treatment success, death, dialysis, or transplantation occurred. Treatment success was defined by a decrease in SCr level to </=1.5 mg/dL for at least 48 hours by day 14 without dialysis, death, or relapse of HRS type 1. RESULTS:Fifty-six subjects were randomized to each arm. Treatment success with terlipressin was double that with placebo (25% vs 12.5%, P = .093). SCr level improved from baseline to day 14 on terlipressin (-0.7 mg/dL) as compared with placebo (0 mg/dL), P < .009. Terlipressin was superior to placebo for HRS reversal (34% vs 13%, P = .008), defined by decrease in SCr level </=1.5 mg/dL. Overall and transplantation-free survival was similar between study groups; HRS reversal significantly improved survival at day 180. One nonfatal myocardial infarction occurred with terlipressin, but the total adverse event rate was similar to placebo. CONCLUSIONS:Terlipressin is an effective treatment to improve renal function in HRS type 1.
RCT Entities:
BACKGROUND & AIMS:Hepatorenal syndrome (HRS) type 1 is a progressive functional renal failure in subjects with advanced liver disease. The aim of this study was to evaluate the efficacy and safety of terlipressin, a systemic arterial vasoconstrictor, for cirrhosis type 1 HRS. METHODS: A prospective, randomized, double-blind, placebo-controlled clinical trial of terlipressin was performed. Subjects with type 1 HRS were randomized to terlipressin (1 mg intravenously every 6 hours) or placebo plus albumin in both groups. The dose was doubled on day 4 if the serum creatinine (SCr) level did not decrease by 30% of baseline. Treatment was continued to day 14 unless treatment success, death, dialysis, or transplantation occurred. Treatment success was defined by a decrease in SCr level to </=1.5 mg/dL for at least 48 hours by day 14 without dialysis, death, or relapse of HRS type 1. RESULTS: Fifty-six subjects were randomized to each arm. Treatment success with terlipressin was double that with placebo (25% vs 12.5%, P = .093). SCr level improved from baseline to day 14 on terlipressin (-0.7 mg/dL) as compared with placebo (0 mg/dL), P < .009. Terlipressin was superior to placebo for HRS reversal (34% vs 13%, P = .008), defined by decrease in SCr level </=1.5 mg/dL. Overall and transplantation-free survival was similar between study groups; HRS reversal significantly improved survival at day 180. One nonfatal myocardial infarction occurred with terlipressin, but the total adverse event rate was similar to placebo. CONCLUSIONS: Terlipressin is an effective treatment to improve renal function in HRS type 1.
Authors: Javier Fernández; Miguel Navasa; Juan Carlos Garcia-Pagan; Juan G-Abraldes; Wladimiro Jiménez; Jaume Bosch; Vicente Arroyo Journal: J Hepatol Date: 2004-09 Impact factor: 25.083
Authors: Tea Restuccia; Rolando Ortega; Monica Guevara; Pere Ginès; Carlo Alessandria; Osman Ozdogan; Miquel Navasa; Antoni Rimola; Juan Carlos Garcia-Valdecasas; Vicente Arroyo; Juan Rodés Journal: J Hepatol Date: 2004-01 Impact factor: 25.083
Authors: F Saner; I Kavuk; H Lang; R Biglarnia; N R Frühauf; R F Schäfers; M Malagó; C E Broelsch Journal: Eur J Med Res Date: 2004-02-27 Impact factor: 2.175
Authors: Thomas D Boyer; Arun J Sanyal; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Veit Gülberg; Samuel Sigal; Alice S Bexon; Peter Teuber Journal: Liver Transpl Date: 2011-11 Impact factor: 5.799
Authors: Brian Erly; William D Carey; Baljendra Kapoor; J Mark McKinney; Mathew Tam; Weiping Wang Journal: Semin Intervent Radiol Date: 2015-12 Impact factor: 1.513
Authors: Olga Baraldi; Chiara Valentini; Gabriele Donati; Giorgia Comai; Vania Cuna; Irene Capelli; Maria Laura Angelini; Maria Ilaria Moretti; Andrea Angeletti; Fabio Piscaglia; Gaetano La Manna Journal: World J Nephrol Date: 2015-11-06
Authors: Anna Licata; Marcello Maida; Ambra Bonaccorso; Fabio Salvatore Macaluso; Maria Cappello; Antonio Craxì; Piero Luigi Almasio Journal: World J Hepatol Date: 2013-12-27
Authors: Juan P Arab; Juan C Claro; Juan P Arancibia; Jorge Contreras; Fernando Gómez; Cristian Muñoz; Leyla Nazal; Eric Roessler; Rodrigo Wolff; Marco Arrese; Carlos Benítez Journal: World J Hepatol Date: 2016-09-08